University Health Network, Toronto
uhn.caLive pipeline data from ClinicalTrials.gov, refreshed daily.
Total trials
1,416
Active
362
Phase 3
96
Total enrollment
359,337
Pipeline matrix
Showing 40 of 176 active programs · click any cell for trials
| Intervention | Early Phase 1 | Phase 1 | Phase 2 | Phase 3 | Phase 4 | N/A | Total |
|---|---|---|---|---|---|---|---|
| 5 mL of 0.25% bupivacaine with epinephrine | — | — | — | — | — | 1 | |
| Semaglutide Treatment | — | — | — | — | — | 1 | |
| Sitagliptin 100mg | — | — | — | — | — | 1 | |
| Intravenous (IV) acetaminophen + oral placebo | — | — | — | — | — | 1 | |
| Intravenous (IV) placebo plus oral acetaminophen | — | — | — | — | — | 1 | |
| Topical TRanexamic Acid | — | — | — | — | — | 1 | |
| Letermovir | — | — | — | — | — | 1 | |
| Valganciclovir/Ganciclovir | — | — | — | — | — | 1 | |
| Teclistamab | — | — | — | — | — | 1 | |
| Tocilizumab | — | — | — | — | — | 1 | |
| Entecavir | — | — | — | — | — | 1 | |
| HBIG | — | — | — | — | — | 1 | |
| Prograf | — | — | — | — | — | 1 | |
| Envarsus | — | — | — | — | — | 1 | |
| Indocyanine Green | — | — | — | — | 4 | ||
| Cisplatin | — | — | 17 | ||||
| Gemcitabine | — | — | — | 9 | |||
| Carboplatin | — | — | 6 | ||||
| Autologous Cold-Stored Platelets | — | — | — | — | — | 1 | |
| Allogeneic Room Temperature-Stored Platelets | — | — | — | — | — | 1 | |
| Adjuvant, non-live RSV vaccine | — | — | — | — | — | 1 | |
| 40 mg Methylprednisolone | — | — | — | — | — | 1 | |
| 80 mg Methylprednisolone | — | — | — | — | — | 1 | |
| Semaglutide 3 MG [Rybelsus] | — | — | — | — | — | 1 | |
| Semaglutide 7 MG [Rybelsus] | — | — | — | — | — | 1 | |
| Semaglutide 14 MG [Rybelsus] | — | — | — | — | — | 1 | |
| efgartigimod | — | — | — | — | — | 1 | |
| Nab paclitaxel | — | — | — | — | — | 1 | |
| H5N1 vaccine | — | — | — | — | — | 1 | |
| Bone Marrow Aspirate (BMA): Minimally manipulated autologous cellular preparation | — | — | — | — | — | 1 | |
| Lipoaspirate Micronized + Leukocyte-Poor Platelet-Rich Plasma (LAM + LP-PRP): Minimally manipulated autologous cellular preparations | — | — | — | — | — | 1 | |
| Modafinil 200mg | — | — | — | — | — | 1 | |
| Lidocaine 20mg/ml | — | — | — | — | — | 1 | |
| Empagliflozin 25 MG | — | — | — | — | — | 1 | |
| Ketamine | — | — | — | — | 3 | ||
| MET-4 | — | — | — | — | 2 | ||
| Cyclophosphamide | — | — | — | — | 11 | ||
| Pembrolizumab | — | — | — | 6 | |||
| Durvalumab | — | — | — | — | 9 | ||
| Nivolumab | — | — | — | 5 |
136 more active programs hidden
Next readouts
- 2020-01-02
- 2021-01-05
- 2022-07-10
- 2024-06-25
- 2024-12-01
- 2024-12-31
- 2025-03-20
- 2025-04-30
- 2025-05
- 2025-06
Top conditions
- Prostate Cancer61
- Breast Cancer50
- Lung Cancer34
- Cancer32
- Colorectal Cancer18
- Head and Neck Cancer18
- Heart Failure18
- Spinal Cord Injuries16
Frequently asked questions about University Health Network, Toronto
- How many clinical trials does University Health Network, Toronto have on ClinicalTrials.gov?
- University Health Network, Toronto is listed as the lead sponsor on 1,416 clinical trials in ClinicalTrials.gov, 362 of which are currently active (recruiting, enrolling, or ongoing).
- How many of University Health Network, Toronto's trials are in Phase 3?
- 96 of University Health Network, Toronto's trials are in Phase 3, spread across 176 active drug programs.
- What therapeutic areas does University Health Network, Toronto focus on?
- University Health Network, Toronto's most-studied conditions on ClinicalTrials.gov are Prostate Cancer, Breast Cancer, Lung Cancer, Cancer, Colorectal Cancer.
- When are University Health Network, Toronto's next clinical trial readouts?
- University Health Network, Toronto has 10 upcoming primary-completion readouts tracked here; the soonest is “Lung Transplant HCV, Pilot Study”, expected around 2020-01-02.